Share
Each spring, the Target ALS Annual Meeting brings members of our Innovation Ecosystem together over three days to share the latest breakthroughs and forge new collaborations, driving progress toward effective treatments for ALS. This year’s meeting had the largest attendance in history, with over 850 attendees present from academic institutions, pharmaceutical and biotech companies, venture capital firms and nonprofit organizations – both in-person and virtually – reflecting the growth of both our funded portfolio of scientists and the impact our work has had on expanding ALS research.
